Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ICCMBullishIndustry Newsnews

High materiality7/10

IceCure kicks off U.S. ChoICE post-marketing study with first site

Jul 27, 2026, 8:37 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Expansion of U.S. clinical sites and 400-patient enrollment supports broader data, potential payer acceptance, and near-term demand for ProSense.

AI summary

What happened, with direct paths to the underlying reporting

IceCure Medical announced West Cancer Center & Research Institute as the first U.S. site for its ChoICE post-marketing study of ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across 30 U.S. sites, generating real-world data to support broader clinical adoption and patient access, potentially fueling near-term demand and longer-term growth.

IceCure names West Cancer Center as first U.S. ChoICE site for ProSense.
ChoICE to enroll up to 400 patients across 30 U.S. sites.
FDA cleared ProSense for 70+ low-risk tumors ≤1.5 cm in Oct 2025.
Sites will serve as ChoICE centers and active commercial sites.
ChoICE aims to expand real-world data and broader access.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.